KZKarla Zadnik

Karla Zadnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karla Zadnik has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial

    by Karla Zadnik, Erica Schulman, Ian Flitcroft, Jennifer S. Fogt, Louis C. Blumenfeld, Tung M. Fong, Eric Lang, Simon P. Chandler, Houman D. Hemmati

    Introduction: Stage 2 of the Childhood Atropine for Myopia Progression (CHAMP) study was conducted to observe the safety, efficacy and rebound effects of low-dose atropine sulphate ophthalmic solutions (0.01% and 0.02%) for paediatric myopia in the year following cessation of 3 years of prior treatment. Methods: The study was a multicentre, randomised, double-masked, placebo-controlled Phase 3 clinical trial. Children aged 3 to < 17 years with myopia (spherical equivalent refractive error (SER) from −0.50 to −6.00 D) who entered and completed Stage 1 (3 years of treatment) participated in the fourth-year follow-up (Stage 2). Stage 1 participants who were treated with atropine 0.01% or 0.02% were re-randomised 1:1:1 to atropine 0.01%, atropine 0.02% or vehicle in Stage 2. Stage 1 vehicle-treated participants were re-randomised 1:1 to atropine 0.01% or atropine 0.02% in Stage 2. Outcomes included changes in cycloplegic SER, changes in axial length (AL), responder status continuity and progression to high myopia. Results: Four hundred and twenty participants were randomised in Stage 2. Negligible rebound was observed among the participants who switched from 0.01% atropine to vehicle compared to those who continued on 0.01% atropine treatment (least square mean difference in SER change from Month 36 to Month 48 between continued treatment and switching to vehicle = 0.019 D, 95% CI [−0.14, 0.18], p = 0.82 for the modified Intent to Treat set). Stage 1 responders remained responders in 83-90% of participants in various Stage 2 groups. Safety profiles were favourable, with mild, transient adverse events. Conclusions: Atropine sulphate ophthalmic solution (0.01%) exhibited negligible rebound in myopia progression after treatment cessation following 3 years of continued treatment, highlighting its potential as a treatment option. The treatment maintained a favourable safety record, and the overall benefit and risk assessment support its potential use as a long-term myopia management option. Clinical trial registration: The Childhood Atropine for Myopia Progression (CHAMP) study was registered in clinicaltrials.gov (NCT03350620, registration date November 17, 2017).


  • Talkin' 'bout my(opia) generation: The impact of Optometry and Vision Science

    by Karla OD Zadnik

    VIRTUAL ISSUE EDITORIAL: This editorial fronts the first virtual issue for Optometry & Vision Science . Virtual issues are a collection of papers from previously published issues of the journal that are brought together in a single, online publication. They highlight the important contribution the journal has made in supporting myopia research. All the papers referenced and previously published in Optometry & Vision Science will be made free access for 1‐month. The collection can be accessed here: https://journals.lww.com/optvissci/pages/collectiondetails.aspx?TopicalCollectionId=16


  • Top Cited Papers

    Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years

    by Karla Zadnik, Erica Schulman, Ian Flitcroft, Jennifer S. Fogt, Louis C. Blumenfeld, Tung M. Fong, Eric Lang, Houman D. Hemmati, Simon P. Chandler, CHAMP Trial Group Investigators, et al.

    Importance: The global prevalence of myopia is predicted to approach 50% by 2050, increasing the risk of visual impairment later in life. No pharmacologic therapy is approved for treating childhood myopia progression.Objective: To assess the safety and efficacy of NVK002 (Vyluma), a novel, preservative-free, 0.01% and 0.02% low-dose atropine formulation for treating myopia progression.Design, Setting, and Participants: This was a double-masked, placebo-controlled, parallel-group, randomized phase 3 clinical trial conducted from November 20, 2017, through August 22, 2022, of placebo vs low-dose atropine, 0.01% and 0.02% (2:2:3 ratio). Participants were recruited from 26 clinical sites in North America and 5 countries in Europe. Enrolled participants were 3 to 16 years of age with −0.50 diopter (D) to −6.00 D spherical equivalent refractive error (SER) and no worse than −1.50 D astigmatism.Interventions: Once-daily placebo, low-dose atropine, 0.01%, or low-dose atropine, 0.02%, eye drops for 36 months.Main Outcomes and Measures: The primary, prespecified end point was the proportion of participants’ eyes responding to 0.02% atropine vs placebo therapy (P = .37) or slow mean SER progression (least squares mean [LSM] difference, 0.10 D; 95% CI, −0.02 D to 0.22 D; P = .10) but did slow mean axial elongation (LSM difference, −0.08 mm; 95% CI, −0.13 mm to −0.02 mm; P = .005); however, at month 36, compared with placebo, low-dose atropine, 0.01%, significantly increased the responder proportion (OR, 4.54; 95% CI, 1.15-17.97; P = .03), slowed mean SER progression (LSM difference, 0.24 D; 95% CI, 0.11 D-0.37 D; P < .001), and slowed axial elongation (LSM difference, −0.13 mm; 95% CI, −0.19 mm to −0.07 mm; P < .001). There were no serious ocular adverse events and few serious nonocular events; none was judged as associated with atropine.Conclusions and Relevance: This randomized clinical trial found that 0.02% atropine did not significantly increase the proportion of participants’ eyes responding to therapy but suggested efficacy for 0.01% atropine across all 3 main end points compared with placebo. The efficacy and safety observed suggest that low-dose atropine may provide a treatment option for childhood myopia progression.Trial Registration: ClinicalTrials.gov Identifier: NCT03350620


  • 2020 Charles F. Prentice Lecture: I Can See Clearly Now

    by Karla OD Zadnik

    The Charles F. Prentice Medal, which was first given the year I was born, is the highest research honor bestowed by the American Academy of Optometry. I received the Prentice Medal in 2020 and gave my presentation at the 2020 American Academy of Optometry meeting, which was entirely virtual. As the first female optometrist to receive the Prentice Medal, I am honored to be given the opportunity to provide this summary of my presentation. Myopia treatment choices to slow the progression of juvenile‐onset myopia, especially in the first year of treatment, range from spectacles to contact lenses to pharmaceuticals. The value of the work described here that aims to predict the onset of myopia in children based on measurements that could be made by the optometrist is about to become more relevant than ever. What if the age‐specific cutpoints could be used to use a low‐risk treatment that would actually prevent the development of myopia altogether?


  • Open Access

    Predicting the onset of myopia in children: results from the CLEERE study

    by Donald O. Mutti, Lisa A. Jordan, Karla Zadnik

    Research often attempts to identify risk factors associated with prevalent disease or that change the probability of developing disease. These factors may also help in predicting which individuals may go on to develop the condition of interest. However, risk factors may not always serve as the best predictive factors and not all predictive factors should be considered as risk factors. A child’s current refractive error, parental history of myopia, and the amount of time children spend outdoors are excellent examples. Parental myopia and time outdoors are meaningful risk factors because they alter the probability of developing myopia and point to important hereditary and environmental influences. A child’s current refractive error points to no particular mechanism and is therefore a poor risk factor. However, it serves as an excellent predictive factor for identifying children likely to develop future myopia. Risk factors may explain how a child reached a particular level of refractive error, but knowledge of that history may not be needed in order to make an accurate prediction about future refractive error. Current refractive error alone may be sufficient. This difference between risk factors and predictive factors is not always appreciated in the literature, including a recent publication in BMC Ophthalmology. This letter attempts to make that distinction and to explain why parental myopia and time outdoors are significant risk factors in the Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error, yet are not significant for predicting future myopia in a multivariate model that contains current refractive error.


  • An Analysis of the Optometric Applicant Pool Relative to Matriculants

    by Karla Zadnik, Lewis N. Reich

    SIGNIFICANCE: The interplay of applicants to optometry school and matriculants has not been explored systematically. It is vital that the profession examines these trends to ensure a viable pipeline of future doctors of optometry. PURPOSE: The purpose of this study was to describe the demographics and academic qualifications of entering optometry classes from autumn 2010 through autumn 2018 of U.S.‐based optometric institutions' application pool and matriculants (enrollees). METHODS: Data were gathered from reports generated from accredited schools and colleges of optometry in the United States and compiled by the Association of Schools and Colleges of Optometry (publicly available) and the Optometry Centralized Application Service. Metrics included the annual number of verified applicants, the annual number of matriculants, the home region of U.S.‐based applicants, and the Optometry Admission Test (OAT) performance and grade point average of verified applicants. RESULTS: The number of verified applicants for autumn 2018 was 0.95% higher than that for autumn 2010, yet the number of matriculants in 2018 compared with 2010 increased by 11.2% with an applicant‐to‐matriculant ratio in 2010 of 1.53 compared with 1.39 in 2018. Grade point average and academic average OAT scores were stable from 2010 to 2018. The ratios of verified applicants with an academic average OAT score of at least 300 to matriculants were 0.87 for autumn 2018 and 0.92 for autumn 2010. The ratios of verified applicants with a grade point average of at least 3.00 to matriculants were 1.13 for autumn 2018 and 1.23 for autumn 2015. CONCLUSIONS: Evidence supports the conclusion that the applicant pool has remained essentially flat for the last decade, whereas the number of matriculants has increased substantially; thus, the number of qualified applicants to matriculants has logically decreased. In the last 2 years, optometric programs have responded by decreasing their institution's number of matriculants to accommodate the national trends.


  • Intrastromal corneal ring segments for treating keratoconus

    by Karla Zadnik, Sarah Money, Kristina Lindsley

    Background Keratoconus is a degenerative condition of the cornea that profoundly affects vision and vision‐specific quality of life. The axial cornea thins and protrudes, resulting in irregularity and, eventually, scarring of the cornea. There are multiple options available for treating keratoconus. Intrastromal corneal ring segments are small, crescent‐shaped plastic rings that are placed in the deep, peripheral corneal stroma in order to flatten the cornea. They are made of polymethylmethacrylate (PMMA). The procedure does not involve corneal tissue nor does it invade the central optical zone. Intrastromal corneal ring segments are approved for use when contact lenses or spectacles are no longer adequate. Objectives To evaluate the effectiveness and safety of intrastromal corneal ring segments as a treatment for keratoconus. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2018, Issue 1); Ovid MEDLINE; Embase.com; PubMed; Latin American and Caribbean Health Sciences Literature Database (LILACS); ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not implement any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 25 January 2018. Selection criteria Two review authors independently assessed records from the electronic searches to identify randomized controlled trials (RCTs). Disagreements were resolved by discussion. Data collection and analysis We planned for two authors to independently review full‐text reports, using standard methodological procedures expected by Cochrane. Main results We found no RCTs comparing intrastromal corneal ring segments with spectacles or contact lenses. Authors' conclusions In the absence of eligible RCTs to review, no conclusions can be drawn.


  • Outdoor Activity Protects Against Childhood Myopia—Let the Sun Shine In

    by Karla Zadnik, Donald O. Mutti

    This Viewpoint discusses the association between childhood myopia and the time that children spend outdoors.


  • Who Says There's Nothing New under the Sun?

    by Karla Zadnik, Donald O. Mutti

    The time since our first publication in 2007 describing time spent outdoors as protective for juvenile myopia onset to clinical trials incorporating outdoor light interventions has been short. The time outdoors/myopia example highlights the incorporation of clinical or epidemiologic evidence to translational research that may eventually change clinical practice and/or behavior.